influenza vaccine
- Generic Name
- influenza vaccine
Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae
- Conditions
- Gonorrhea Male
- Interventions
- Biological: Neisseria gonorrhoeae strain FA1090Biological: Tetanus-diptheria Vaccine
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 140
- Registration Number
- NCT05294588
- Locations
- 🇺🇸
Clinical and Translational Research Center (CTRC) at University of North Carolina (UNC) Hospitals and/or at UNC Global Clinical Research North, Chapel Hill, North Carolina, United States
🇺🇸Clinical and Translational Research Center (CTRC) at University of North Carolina (UNC) Hospitals and/or at UNC Global Clinical Research North, Chapel Hill, North Carolina, United States
A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults
- Conditions
- COVID-19 Prevention
- Interventions
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 861
- Registration Number
- NCT05091307
- Locations
- 🇺🇸
Wr McCr Llc, San Diego, California, United States
🇵🇱Synexus Polska Sp z o o Oddzial w Katowicach, Katowice, Poland
🇵🇱Synexus Polska Sp Z O O Oddzial W Lodzi, Lodz, Poland
Beta-glucan and Immune Response to Influenza Vaccine
- Conditions
- Healthy Aging
- Interventions
- First Posted Date
- 2021-10-12
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 78
- Registration Number
- NCT05074303
- Locations
- 🇺🇸
Food Science and Human Nutrition Department, University of Florida, Gainesville, Florida, United States
Influenza Vaccine in Lung Transplant Patients - T Cells
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2020-10-23
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 24
- Registration Number
- NCT04533061
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
Influenza Vaccine in Lung Transplant Patients - Antibody
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2020-10-23
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 122
- Registration Number
- NCT04533139
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies Beyond the Season
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2020-10-23
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 100
- Registration Number
- NCT04530786
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2020-10-23
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 139
- Registration Number
- NCT04531787
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
Influenza Vaccine in Lung Transplant Patients - Seroprotection
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2020-10-23
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 79
- Registration Number
- NCT04531657
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Robert J. Pignolo
- Target Recruit Count
- 61
- Registration Number
- NCT04176133
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
VSMART (Video-Conference Stress Management and Relaxation Training for Older Women With Breast Cancer)
- First Posted Date
- 2019-05-20
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 120
- Registration Number
- NCT03955991
- Locations
- 🇺🇸
Flipse Building, Coral Gables, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.